Stuart Roberts

• 
  www.sceq.com.au/services_research.aspx - [Cached Version]
  Published on: 3/3/2008    Last Visited: 3/3/2008  

  Stuart Roberts
  ...
  Stuart Roberts
  ...
  Stuart Roberts
  
  Stuart Roberts, Director of Research and Healthcare and Biotechnology Analyst: Stuart has been an analyst at Southern Cross Equities in Sydney since April 2001.Stuart is a journalist by training and has complimented these skills with a Masters Degree in Finance from Finsia.Stuart has previously worked at the ASX and investor publication firms ... Stuart is an avid researcher of his chosen speciality.

• 
  www.resourcefulevents.com/biotechnology-conference/_his - [Cached Version]
  Published on: 3/19/2007    Last Visited: 12/4/2007  

  Chaired by Stuart Roberts, Research Analyst, Southern Cross Equities
  ...
  Chaired by Stuart Roberts, Research Analyst
  ...
  Chaired by Stuart Roberts, Research Analyst
  ...
  Chaired by Stuart Roberts, Research Analyst, Southern Cross Equities
  ...
  Chaired by Stuart Roberts, Research Analyst, Southern Cross Equities

• 
  www.sceq.com.au/public/contact.asp?id=Stuart%20Roberts - [Cached Version]
  Published on: 5/21/2007    Last Visited: 5/21/2007  

  Stuart RobertsSouthern Cross Equities - Contact Us
  ...
  Stuart Roberts

• 
  www.resourcefulevents.com/biotechnology-conference/_his - [Cached Version]
  Published on: 1/1/2007    Last Visited: 12/4/2007  

  Chaired by Stuart Roberts, Research Analyst
  ...
  Chaired by Stuart Roberts, Research Analyst
  ...
  Stuart Roberts, Research Analyst
  ...
  Chaired by Stuart Roberts, Research Analyst

• 
  ATP Innovations - [Cached Version]
  Published on: 2/7/2006    Last Visited: 11/2/2006  

  STUART ROBERTSAnalystSouthern Cross Equities
  
  Stuart Roberts is an analyst at Southern Cross Equities, a Sydney-based institutional stockbroking firm.He got into biotechnology in early 2002 because Southern Cross clients were losing money in the area, but hung around once the bull market of 2003 got going because by then he had discovered a strong passion for both the science and the business of biotech.Stuart is the author of the Australian Biotechnology Buzz, a regular newsletter covering developments in the Life Sciences and the performance of Australian listed biotech companies.

• 
  EvoGenix / For Investors / Research Coverage - [Cached Version]
  Published on: 4/6/2006    Last Visited: 2/8/2008  

  Report on EvoGenix by Stuart Roberts of Southern Cross Equities

• 
  Excellence in Biotechnology and Investment: Agenda - [Cached Version]
  Published on: 3/19/2007    Last Visited: 7/30/2007  

  Chaired by Stuart Roberts, Research Analyst
  ...
  Chaired by Stuart Roberts, Research Analyst
  ...
  Stuart Roberts, Research Analyst
  ...
  Chaired by Stuart Roberts, Research Analyst
  ...
  Chaired by Stuart Roberts, Research Analyst, Southern Cross Equities
  ...
  Chaired by Stuart Roberts, Research Analyst
  ...
  Chaired by Stuart Roberts, Research Analyst
  ...
  Chaired by Stuart Roberts, Research Analyst, Southern Cross Equities
  ...
  Chaired by Stuart Roberts, Research Analyst, Southern Cross Equities

• 
  IP Australia : IP Professor - [Cached Version]
  Published on: 9/27/2004    Last Visited: 1/16/2006  

  Southern Cross Equities biotechnology analyst, Stuart Roberts, says the patent allows the company greater freedom.Peplin Biotech shares have risen three cents to 73 cents after heavy trading.

• 
  Message - [Cached Version]
  Published on: 12/10/2005    Last Visited: 9/10/2006  

  Editor: Stuart Roberts, Biotechnology Analyst, Southern Cross Equities, Telephone 61-2-8224-2871.
  ...
  Stuart Roberts,
  
  Biotechnology
  
  Analyst,

• 
  News Article - [Cached Version]
  Published on: 5/10/2003    Last Visited: 8/22/2006  

  Analyst Stuart Roberts of Southern Cross Equities agrees biotechnology is maturing in Australia, that managers are more savvy and companies are growing.The typical company is capitalised at $60 million.
  
  Roberts said biotechnology first became an asset class in 1986 but now is a good time to invest.
  
  "It takes about 12 years to get a drug approved, so we are only just getting to the stage where companies can have a shot at the big time," he said.
  
  Shares have reached and exceeded his target prices but he believes there is still value in the sector.

Page:  1 2